[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Yoshimatsu K, Kuhara K, Itagaki H, Aizawa M, Yokomizo H, Fujimoto T, Otani T, Osawa G, Kobayashi R, Ogawa K: Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer. Anticancer Res; 2008 Jan-Feb;28(1B):373-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer.
  • Anticancer drugs may frequently induce host immunosuppression and symptomatic toxicities.
  • Since little is known of the relationship between host immunity and the toxicity of chemotherapy, the host immunity before and after chemotherapy was compared to assess whether it is related to symptomatic toxicity during chemotherapy.
  • PATIENTS AND METHODS: Fourteen patients with colorectal cancer underwent leucovorin /5-fluorouracil (LV/5-FU) treatment, or S-1/irinotecan (CPT-11).
  • Host immunity (cytokine production of peripheral blood mononuclear cell (PBMC), serum soluble interleukin-2 receptor (sIL-2R) levels and phenotypic analyses of PBMC were measured before and after the first chemotherapy.
  • These changes in the first chemotherapy were significantly different (p = 0.0211, p = 0.0087, p = 0.0234).
  • CONCLUSION: The current study indicated that there are some parameters correlated with toxicity during chemotherapy which effect QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / immunology
  • [MeSH-minor] Aged. CD4-CD8 Ratio. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Cytokines / biosynthesis. Drug Combinations. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology. Male. Middle Aged. Neoplasm Staging. Oxonic Acid / administration & dosage. Oxonic Acid / adverse effects. Quality of Life. Receptors, Interleukin-2 / biosynthesis. Receptors, Interleukin-2 / blood. T-Lymphocytes / drug effects. T-Lymphocytes / immunology. Tegafur / administration & dosage. Tegafur / adverse effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383872.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cytokines; 0 / Drug Combinations; 0 / Receptors, Interleukin-2; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


2. Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD: Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl; 2005 May;11(5):497-503
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
  • To confirm recent observations about the relationship between immunosuppression and the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), we retrospectively analyzed 70 consecutive HCC patients who underwent LT and received cyclosporine (CsA)-based immunosuppression.
  • CsA trough blood levels, measured with the same technique (fluorescence polarization immunoassay), were analyzed at different time points after transplantation.
  • The exposure to the drug was calculated with the trapezoidal rule in each patient.
  • Different immunosuppressive schedules (CsA and steroids vs. CsA, steroids, and azathioprine) or the cumulative dosage of steroids and azathioprine did not influence HCC recurrence that was associated instead with CsA exposure (278.3 +/- 86.4 ng/mL in recurrent vs. 169.9 +/- 33.3 in tumor-free patients; P < 0.001); CsA exposure above 189.6 ng/mL was related to HCC recurrence at the receiver operating characteristic analysis (ROC).
  • The relationship between CsA exposure; various clinical (sex, age, viral- vs. non-viral-related cirrhosis, preoperative vs. incidental diagnosis of HCC, alpha-fetoprotein [AFP] blood level), pathologic (pathologic tumor staging [pT] stage, presence of Milan criteria), and histologic (grading, presence of microvascular tumor invasion) parameters; and tumor recurrence were assessed.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Immunosuppression / adverse effects. Liver Neoplasms / epidemiology. Liver Transplantation / statistics & numerical data. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Cyclosporine / adverse effects. Cyclosporine / blood. Disease-Free Survival. Female. Graft Rejection / drug therapy. Graft Rejection / epidemiology. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / blood. Male. Middle Aged. ROC Curve. Risk Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2005 May;11(5):494-6 [15838915.001]
  • (PMID = 15838913.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


3. Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF: AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis; 2008;18(2 Suppl 2):S2-189-94
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy.
  • Implementation of highly active antiretroviral therapy (HAART) has resulted in a dramatic reduction in the HIV/AIDS morbidity and mortality.
  • The present study evaluates the neoplasm prevalence before and after the implementation of HAART.
  • Neoplasm prevalence was measured, and the difference in AIDS- and non-AIDS-defining neoplasms was analyzed before and after the HAART era.
  • DISCUSSION: Our study found a significant reduction of Kaposi sarcoma and AIDS-related lymphoma in the HAART era of the AIDS epidemic.
  • These findings suggest that factors other than severe immunosuppression are involved in the neoplasms' pathogenesis.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2006 Nov;61(11):1000-8 [17071836.001]
  • [Cites] MMWR Suppl. 1987 Aug 14;36(1):1S-15S [3039334.001]
  • [Cites] J Behav Med. 2007 Oct;30(5):371-83 [17570050.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2417-9 [16735700.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):223-8 [10889597.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):480-2 [11391169.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] AIDS. 2003 Oct 17;17(15):2227-36 [14523280.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-57-62 [16312941.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Clin Infect Dis. 2003 Apr 15;36(8):1030-8 [12684916.001]
  • (PMID = 18646347.001).
  • [ISSN] 1049-510X
  • [Journal-full-title] Ethnicity & disease
  • [ISO-abbreviation] Ethn Dis
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / G12 MD007583; United States / NCRR NIH HHS / RR / U54 RR019507; United States / NCRR NIH HHS / RR / G12RR03035; United States / NCRR NIH HHS / RR / 1U54RR01950701; United States / NCRR NIH HHS / RR / G12 RR003035
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS425729; NLM/ PMC3546505
  •  go-up   go-down


Advertisement
4. Sissolak G, Mayaud P: AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health; 2005 Oct;10(10):981-92
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa.
  • Until the 1980s, little attention had been accorded to endemic Kaposi's sarcoma (KS), a neoplasm noted in several parts of Southern Europe and the African continent but with relatively slow progression, except in children and young adults.
  • Furthermore, therapeutic approaches based on surgery, radiation and topical treatment were of limited efficacy, mostly used to overcome the disabling and stigmatizing effects of the disease.
  • With the emergence of the HIV/AIDS epidemic, and the profound impact of KS on AIDS-related mortality, the pathogenesis of KS has been better studied, and the realisation that a virus (KS-associated Herpesvirus or Human Herpesvirus 8, or KSHV/HHV-8), combined with immunosuppression and cytokine-induced growth, was responsible for the development of this disease has led to novel therapeutic approaches.
  • However, the use of highly active antiretroviral therapy (HAART), which has led to a considerable decline in KS incidence in populations of industrialized countries, constitutes the best hope for the control of this stigmatizing and lethal disease in Africa.
  • Trials comparing different regimens of antiretroviral drugs in combination with systemic chemotherapeutic agents are urgently needed.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / epidemiology. Adult. Africa South of the Sahara / epidemiology. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active / methods. Developing Countries / statistics & numerical data. Herpesviridae Infections / epidemiology. Herpesviridae Infections / etiology. Herpesviridae Infections / therapy. Herpesvirus 8, Human. Humans. Interferon-alpha / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185232.001).
  • [ISSN] 1360-2276
  • [Journal-full-title] Tropical medicine & international health : TM & IH
  • [ISO-abbreviation] Trop. Med. Int. Health
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 95
  •  go-up   go-down


5. Cescon M, Grazi GL, Assietti R, Scanni A, Frigerio F, Sparacio F, Ercolani G, Cavallari A: Embryonal rhabdomyosarcoma of the orbit in a liver transplant recipient. Transpl Int; 2003 Jun;16(6):437-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although an increased incidence of de novo malignancies is reported in transplant recipients, rhabdomyosarcoma, an aggressive mesenchymal tumor typical of childhood, is not considered a neoplasm commonly related to immunosuppression.
  • Since the patient refused complete orbital excision, one course of radiotherapy and six courses of chemotherapy were administered, while immunosuppression was re-modulated, without interruption of the administration of cyclosporine.
  • Complete control of tumor growth was achieved, while no alterations of graft function were observed throughout the treatment period.
  • [MeSH-minor] Adult. Female. Humans. Immunosuppression / adverse effects. Liver / physiopathology. Magnetic Resonance Imaging. Male. Reoperation. Treatment Outcome


6. Zhang PL, Malek SK, Prichard JW, Lin F, Yahya TM, Schwartzman MS, Latsha RP, Skaletsky M, Norfolk ER, Brown RE, Hartle JE, Potdar S: Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression. Ann Clin Lab Sci; 2004;34(2):209-13
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
  • The resultant imbalance of lymphocytes and monocytes after Campath-1H treatment of a renal-transplant recipient may lead to an acute rejection dominated by monocytes.
  • We report such a case of acute transplant rejection in a 49-yr-old man who received a living non-related kidney transplant and was treated with preoperative Campath-1H and postoperative immunosuppression.
  • After steroid treatment for 2 wk, the patient's serum creatinine concentration diminished to 1.5 mg/dl.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Graft Rejection / immunology. Immunosuppressive Agents / therapeutic use. Kidney Transplantation. Monocytes / immunology. Mycophenolic Acid / analogs & derivatives
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antigens, CD / blood. Antigens, CD / immunology. Antigens, CD34 / blood. Antigens, CD34 / immunology. Antigens, Differentiation, Myelomonocytic / blood. Antigens, Differentiation, Myelomonocytic / immunology. Antigens, Neoplasm / blood. Antigens, Neoplasm / immunology. Drug Therapy, Combination. Glycoproteins / blood. Glycoproteins / immunology. Humans. Male. Middle Aged. Postoperative Care. Prednisone / therapeutic use. Preoperative Care

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15228236.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / CD68 antigen, human; 0 / Glycoproteins; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; VB0R961HZT / Prednisone
  •  go-up   go-down


7. Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H: Strategies in the management of alemtuzumab-related side effects. Semin Oncol; 2006 Apr;33(2 Suppl 5):S29-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies in the management of alemtuzumab-related side effects.
  • The introduction of alemtuzumab, a CD52 monoclonal antibody with significant clinical activity in chemotherapy refractory B-cell chronic lymphocytic leukemia, is accompanied by a side effect profile different from that resulting from chemotherapy.
  • The intravenous administration of alemtuzumab is usually accompanied by transient infusion-related side effects manifesting primarily as flu-like symptoms.
  • These reactions can be reduced by use of corticosteroid prophylaxis, and will subside gradually during continued treatment.
  • Neutropenia (grade 4) may occur in approximately 20% of patients, but is usually transient and/or responds promptly to colony stimulating factor therapy; episodes of febrile neutropenia are infrequent.
  • This event typically occurs 3 to 8 weeks after initiation of therapy, coinciding with the T-cell nadir.
  • With vigilance and early detection, these infections are usually manageable and do not cause organ failure.
  • Preliminary data indicate that other infections following alemtuzumab therapy do not seem to occur at a frequency that is higher than expected, probably because of the general prophylactic use of cotrimoxazole (trimethoprim and sulfamethoxazole) and valacyclovir in combination with clinical tumor regressions.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Antineoplastic Agents / adverse effects
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bacterial Infections / prevention & control. Drug Eruptions / prevention & control. Humans. Immunosuppression / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Neutropenia / prevention & control. T-Lymphocytes / drug effects. Virus Diseases / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720201.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 35
  •  go-up   go-down


8. Haider I, Cahill M: Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology; 2004 Oct-Dec;9(5-6):409-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy.
  • Alemtuzumab is associated with severe immunosuppression, allergic reactions and thrombocytopenia.
  • Data sheet and information supplied by the manufacturer confirm the rare occurrence of serious immune thrombocytopenia, recommending discontinuation of therapy when platelet counts fall below 50x10(9)/l.
  • We report a patient with refractory CLL in which relentless progressive cytopenia occurred despite the discontinuation of alemtuzumab therapy while the platelet count was over 97x10(9)/l.
  • Data on the predictive factors underlying this complication are few and deserve further study as this drug is increasingly used the treatment of CLL.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Antineoplastic Agents / adverse effects. Cerebral Hemorrhage / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / prevention & control. Thrombocytopenia / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763982.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


9. Pitman SD, Huang Q, Zuppan CW, Rowsell EH, Cao JD, Berdeja JG, Weiss LM, Wang J: Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol; 2006 Apr;30(4):470-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Hodgkin lymphoma-like posttransplantation lymphoproliferative disorder (HL-like PTLD) has been grouped with classic Hodgkin lymphoma type PTLD (HL-PTLD), controversy remains as to whether it is truly a form of HL or whether it should be more appropriately classified as a form of B-cell PTLD.
  • PTLD developed from 4 months to 6 years following solid organ transplantation (3 hearts, 1 kidney, 1 liver), and involved both nodal and extranodal sites.
  • All were EBV-related (EBER+) with the large neoplastic cells CD20/CD79a positive but CD15 negative.
  • All patients were managed by initial reduction/withdrawal of immunosuppression, with 2 also receiving chemotherapy for non-HL.
  • [MeSH-minor] Adolescent. Adult. Child. Clone Cells. DNA, Neoplasm / analysis. Diagnosis, Differential. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / pathology. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunocompromised Host. Immunosuppression. Infant. Male. Middle Aged. Postoperative Complications. RNA, Viral / analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625093.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


10. Buckanovich RJ, Liu G, Stricker C, Luger SM, Stadtmauer EA, Schuster SJ, Duffy K, Tsai D, Pruitt A, Porter DL: Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann Hematol; 2002 Jul;81(7):410-3
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This approach is particularly attractive for patients who have received extensive prior therapy and are poor candidates for traditional allogeneic stem cell transplantation.
  • Additional immunosuppression in already immunocompromised patients may result in unexpected toxicity.
  • The patient developed severe neurological symptoms approximately 6 weeks following NMASCT associated with low CD4+ cell counts and magnetic resonance imaging (MRI) was consistent with PML.
  • IL-2 therapy resulted in increasing CD4+ counts and progressive resolution of neurological symptoms.
  • Disruption of IL-2 therapy led to neurological deterioration, which responded to reinstitution of IL-2 therapy.
  • However, it demonstrates the potential for severe complications related to immunosuppression, especially in heavily pretreated patients.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / surgery. Interleukin-2 / therapeutic use. Leukoencephalopathy, Progressive Multifocal / drug therapy. Leukoencephalopathy, Progressive Multifocal / etiology. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Immunosuppression / adverse effects. Leukocyte Transfusion. Liver Diseases / etiology. Liver Diseases / radiography. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Transplantation, Homologous

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12185517.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


11. Heise W: GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):57-69
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal lymphoma plays a major role complicating different diseases presenting with immunosuppression, both primary and acquired immunodeficiency (incl.
  • HIV, transplantation, immunosuppression following chemotherapy, or inflammatory bowel disease).
  • Lymphoma in diseases with immunosuppression are clinically and pathologically heterogeneous, but share some features such as frequent involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, viral association with EBV and clinically aggressive courses.
  • While gastrointestinal lymphoma in congenital immunodeficiency disorders seems to be a rare event inspite of higher prevalences, in post-transplant lymphoproliferative disorders (PTLD) the gastrointestinal tract is one of the most important organs of lymphoma.
  • In HIV-associated non-Hodgkin's lymphoma, gastrointestinal lesions as the most frequent extranodal localisation occur in 30-50% of lymphoma patients, are late events of HIV infection with severe immunosuppression and are mainly diagnosed with advanced disease stages Ann Arbour III or IV.
  • With the introduction of highly active antiretroviral therapy (HAART) in the therapeutic concept in AIDS, a decrease of AIDS-related GI lymphoma was noted with improved survival rates and prognosis of lymphoma.
  • Therapy strategies including chemotherapy, immunotherapy and HAART will show promising results in response and survival rates.
  • [MeSH-major] Gastrointestinal Neoplasms / immunology. HIV Infections / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymphoma / immunology. Lymphoma, AIDS-Related / immunology. Organ Transplantation
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Endoscopy, Gastrointestinal. Humans. Immunotherapy / methods. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206109.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 84
  •  go-up   go-down


12. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL: Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation; 2003 Jul 27;76(2):370-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
  • BACKGROUND: Human immunodeficiency virus (HIV)-infected patients have historically been excluded from consideration for transplantation out of concern for the effects of immunosuppression on the progression of HIV disease.
  • Improvements in HIV-related morbidity and mortality with the use of highly active antiretroviral therapy (HAART) have prompted a reevaluation of transplantation as a treatment option for HIV-infected patients with end-stage kidney and liver disease.
  • They had undetectable plasma HIV-1 RNA levels (viral load) for 3 months (kidney) or were predicted to achieve viral load suppression posttransplantation if unable to tolerate HAART (liver); a CD4+ T-cell count of more than 200 cells/microL (kidney) or more than 100 cells/microL (liver) for 6 months; and no history of opportunistic infections and neoplasm.
  • Standard immunosuppression included prednisone, mycophenolate mofetil (CellCept, Roche Pharmaceuticals, Basel, Switzerland), and cyclosporine (Neoral, Novartis, East Hanover, NJ).
  • Preliminary data are encouraging and indicate that transplantation should be a treatment option for individuals with well-controlled HIV disease.
  • [MeSH-minor] Adult. Anti-HIV Agents / pharmacokinetics. Antiretroviral Therapy, Highly Active. Drug Interactions. Female. Graft Survival. Humans. Immunosuppression. Immunosuppressive Agents / pharmacokinetics. Male. Middle Aged. Pilot Projects


13. McCoy MJ, Nowak AK, Lake RA: Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens; 2009 Jul;74(1):1-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.
  • Over recent years, there has been increasing interest in the possibility of combining immunotherapy with chemotherapy in the fight against cancer.
  • Here, we discuss the rationale behind combining these two, long considered antagonistic, treatment options in the context of malignant mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Antineoplastic Agents / therapeutic use. Immunosuppression. Mesothelioma / therapy. Neoplasms, Mesothelial / therapy
  • [MeSH-minor] Combined Modality Therapy. Cytokines / immunology. Cytokines / metabolism. Humans

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422663.001).
  • [ISSN] 1399-0039
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cytokines
  • [Number-of-references] 93
  •  go-up   go-down


14. Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE: [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab]. Tidsskr Nor Laegeforen; 2004 Mar 18;124(6):768-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
  • [Transliterated title] Behandling av T-prolymfocyttleukemi med monoklonalt anti-CD52-antistoff (alemtuzumab).
  • It has generally been resistant to alkylating chemotherapy, but some effect has been observed with the purine analog 2-deoxycoformicin with documented partial or complete response rates in up to 45% of patients.
  • Treatment with monoclonal antibodies against CD 52 has been shown to be highly effective in T-PLL with response rates of up to 76%.
  • This may allow for further consolidating treatment with high-dose chemotherapy with autologous stem cell support or allogeneic stem cell transplantation.
  • The treatment is generally well tolerated; the principal management problem is immunosuppression, as shown in one patient who developed a varicella-zoster meningoencephalomyelitis as a consequence of not receiving antiviral prophylaxis.
  • The main infusion-related adverse effects are fever and chills.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15039804.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


15. Schultz CJ, Bovi J: Current management of primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys; 2010 Mar 1;76(3):666-78
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous cell lymphoma (PCNSL) is an uncommon neoplasm of the brain, leptomeninges, and rarely the spinal cord.
  • Initially thought to be characteristically associated with congenital, iatrogenic, or acquired immunosuppression, PCNSL is now recognized with increasing frequency in immunocompetent individuals.
  • A whole-brain radiation volume has empirically been used to adequately address the multifocal tumor frequently encountered at the time of PCNSL diagnosis.
  • Chemotherapy alone or in combination with WBRT has more recently become the treatment of choice.
  • High response rates and improved survival with the use of chemotherapy has led to treatment strategies that defer or eliminate WBRT in hopes of lessening the risk of neurotoxicity attributed to WBRT.
  • Combined chemotherapy and WBRT regimens are now being explored that use lower total doses of radiation and altered fractionation schedules with the aim of maintaining high rates of tumor control while minimizing neurotoxicity.
  • Pretreatment, multifactor prognostic indices have recently been described that may allow selection of treatment regimens that strike an appropriate balance of risk and benefit for the individual PCNSL patient.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy / methods. Cranial Irradiation / adverse effects. Diagnostic Imaging / methods. Humans. Immunocompetence. Lymphoma, AIDS-Related / therapy. Prognosis. Radiotherapy Planning, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20159361.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 72
  •  go-up   go-down


16. Seeley K, DeMeyer E: Nursing care of patients receiving Campath. Clin J Oncol Nurs; 2002 May-Jun;6(3):138-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal antibodies are focused therapies with unique infusion-related complications.
  • Campath (alemtuzumab, Berlex Laboratories, Richmond, CA) is indicated for the treatment of refractory chronic lymphocytic leukemia and has a complicated administration schedule, severe infusion-related toxicity, and profound immunosuppressive capability.
  • Management of complicated therapies, such as Campath, stretches resources and requires a coordinated effort by the healthcare team for successful patient outcomes.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Nursing Care
  • [MeSH-minor] Ambulatory Care. Antibodies, Monoclonal, Humanized. Drug Administration Schedule. Humans. Immunosuppression / nursing. Patient Care Planning. Patient Education as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11998606.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


17. Ohashi H, Kato C, Fukami S, Saito H, Hamaguchi M: Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases. Am J Hematol; 2005 Jun;79(2):142-6
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases.
  • One patient underwent peripheral blood stem cell transplantation (SCT) from a related, yet haplotype-mismatched, donor for chronic myelomonocytic leukemia.
  • In the other patient, with acute lymphoblastic leukemia, systemic relapse occurred when he was still on immunosuppression 6 months after SCT from an unrelated donor.
  • After induction chemotherapy following cessation of immunosuppression, the BM examination proved CR.
  • During consolidation chemotherapy, however, he developed leukemic dissemination in the CSF, despite the fact that the BM was in CR.
  • In both patients, the BM cells and all the fractions of the PB cells proved donor-type chimeras.
  • [MeSH-major] Bone Marrow / pathology. Central Nervous System Neoplasms / therapy. Leukemia / therapy. Neoplasm Recurrence, Local. Peripheral Blood Stem Cell Transplantation. Tissue Donors. Transplantation Chimera
  • [MeSH-minor] Adult. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelomonocytic, Chronic / pathology. Leukemia, Myelomonocytic, Chronic / therapy. Male. Middle Aged. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929112.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Davies JQ, de la Hall PM, Kaschula RO, Sinclair-Smith CC, Hartley P, Rode H, Millar AJ: Hepatoblastoma--evolution of management and outcome and significance of histology of the resected tumor. A 31-year experience with 40 cases. J Pediatr Surg; 2004 Sep;39(9):1321-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: The aim of this study was to retrospectively evaluate and compare the clinical features, treatment strategy, pathology, and outcome of all patients with hepatoblastoma treated at an African hospital over a 31-year period (1970 to 2001).
  • METHODS: Forty patients with hepatoblastoma were divided into 3 groups according to the treatment given.
  • Group I (1970 to 1983, 14 patients) had no protocol therapy; group II (1984 to 1988, 6 patients) received protocol treatment according to Children's Study Group (CCSG) guidelines; group III (1989 to 2001, 20 patients) received SIOPEL protocol therapy.
  • Deaths in group II were caused by chemotherapy-induced immunosuppression only.
  • Prognostic data for group III showed that all tumor-related deaths could be predicted by identifying multifocal disseminated growth patterns (P =.001) or vascular invasion (P =.001) in resected tumors.
  • CONCLUSIONS: The introduction of protocol therapy has resulted in a marked improvement in survival.
  • Immunosuppression-related sepsis in our setting resulted in unacceptable mortality in patients treated according to CCSG guidelines.
  • Preoperative chemotherapy followed by complete surgical excision according to International Society of Paediatric Oncology guidelines yields excellent results with a current survival rate of 80%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatoblastoma / surgery. Liver Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Case Management / trends. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Hepatectomy. Humans. Immunocompromised Host. Infant. Infant, Newborn. Lung Neoplasms / secondary. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Sepsis / etiology. Sepsis / mortality. South Africa / epidemiology. Survival Analysis. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15359384.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; AP protocol 1
  • [Number-of-references] 33
  •  go-up   go-down


19. Cersosimo RJ: Monoclonal antibodies in the treatment of cancer, Part 2. Am J Health Syst Pharm; 2003 Aug 15;60(16):1631-41; quiz 1642-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibodies in the treatment of cancer, Part 2.
  • Monoclonal antibodies used in the treatment of cancer are discussed.
  • Gemtuzumab ozogamicin is an active second-line therapy in older patients with acute myelogenous leukemia, but its role in combination regimens is unclear.
  • Alemtuzumab is a valuable option for salvage therapy of patients with chronic lymphocytic leukemia.
  • Ibritumomab tiuxetan delivers radioactive isotopes to tumor cells and is active against indolent lymphomas in patients who have relapsed after chemotherapy or rituximab therapy.
  • The most common adverse effects of monoclonal antibodies are myelosuppression, infusion-related reactions, and hypersensitivity reactions.
  • Alemtuzumab causes immunosuppression, increasing the risk of infection.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Aminoglycosides / administration & dosage. Aminoglycosides / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / administration & dosage. Antibodies, Neoplasm / therapeutic use. Humans. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12966906.001).
  • [ISSN] 1079-2082
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / gemtuzumab; 0 / ibritumomab tiuxetan; 3A189DH42V / alemtuzumab
  • [Number-of-references] 177
  •  go-up   go-down


20. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM: Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol; 2010 Feb 20;28(6):1038-46
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS We examined the clinical features and outcomes among a large cohort of solid organ transplantation (SOT) -related patients with PTLD who were recently treated at four Chicago institutions (from January 1998 to January 2008).
  • Results Eighty patients with PTLD were identified who had a median SOT-to-PTLD time of 48 months (range, 1 to 216 months).
  • All patients had reduction of immunosuppression as part of initial therapy, whereas 59 (74%) of 80 patients received concurrent first-line rituximab with or without chemotherapy.
  • Patients who received rituximab-based therapy as part of initial treatment had 3-year PFS of 70% and OS 73% compared with 21% (P < .0001) and 33% (P = .0001), respectively, without rituximab.
  • CONCLUSION This large, multicenter, retrospective analysis suggests significantly improved PFS and OS associated with early rituximab-based treatment in PTLD.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2006 Jan 27;81(2):175-80 [16436959.001]
  • [Cites] Transplantation. 2002 Oct 27;74(8):1095-102 [12438953.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Lancet. 1993 Dec 18-25;342(8886-8887):1514-6 [7902900.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):214-21 [7779838.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3333-40 [7579436.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2052-9 [9626203.001]
  • [Cites] Lancet. 1998 Sep 5;352(9130):789 [9737292.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):191-6 [15621801.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):775-80 [15760401.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Transplantation. 2005 Jul 27;80(2):193-7 [16041263.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1661-7 [16149091.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7574-82 [16186599.001]
  • [Cites] Am J Transplant. 2005 Dec;5(12):2901-6 [16303003.001]
  • [Cites] Transplantation. 2005 Nov 15;80(9):1233-43 [16314791.001]
  • [Cites] Transplantation. 2005 Dec 27;80(12):1692-8 [16378063.001]
  • [Cites] Lancet. 2006 Jan 21;367(9506):233-9 [16427492.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):222-30 [14974943.001]
  • [Cites] Am J Transplant. 2006 Mar;6(3):569-76 [16468968.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3053-7 [16254143.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Transplantation. 2006 Aug 15;82(3):375-81 [16906036.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Haematologica. 2007 Feb;92(2):273-4 [17296588.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4648-56 [17925562.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4902-8 [17971586.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1489-94 [18024397.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1738-44 [18798108.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3186-91 [18846563.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3354-62 [19451438.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):375-85 [10716151.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3622-32 [11054435.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):772-8 [11157030.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1076-88 [11374406.001]
  • [Cites] Recent Results Cancer Res. 2002;159:67-80 [11785846.001]
  • [Cites] Haematologica. 2002 Jan;87(1):67-77 [11801467.001]
  • [CommentIn] J Clin Oncol. 2010 Jul 20;28(21):e366; author reply e367-8 [20479392.001]
  • [CommentIn] Nat Rev Clin Oncol. 2010 May;7(5):240 [20432523.001]
  • (PMID = 20085936.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109613-05; United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / K23 CA109613-A1; United States / NCI NIH HHS / CA / K23 CA109613-05; United States / NCI NIH HHS / CA / K23 CA109613-04; United States / NCI NIH HHS / CA / CA109613-04
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2834429
  •  go-up   go-down


21. Cogle CR, Moreb JS, Leather HL, Finiewicz KJ, Khan SA, Reddy VS, Wingard JR: Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Am J Hematol; 2003 Jul;73(3):169-75
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autologous stem cell transplantation (ASCT) has enabled the use of high-dose alkylating agents either as a single agent or in combination with other cytotoxic agents and/or total body irradiation (TBI) for the treatment of multiple myeloma.
  • Despite improved complete remission rates, relapse and regimen-related toxicities remain challenging.
  • In an effort to increase event-free survival and decrease the high incidence of regimen-related toxicity, we have studied the use of etoposide in combination with reduced-dose busulfan and cyclophosphamide as a conditioning regimen for ASCT in a group of 26 patients with advanced multiple myeloma.
  • There was no early treatment-related mortality.
  • Post-engraftment, 10 patients (38%) achieved CR, 15 (58%) patients achieved PR or SD, and 1 patient developed progressive disease (4%).
  • The median times for event-free survival and overall survival after transplantation were 24 and 43 months, respectively.
  • In conclusion, conditioning with busulfan, cyclophosphamide, and etoposide followed by ASCT is a safe regimen with comparable effectiveness to other previously used preparative regimens, thus providing another approach of non-TBI containing high-dose chemotherapy for patients with multiple myeloma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Immunosuppression / methods. Male. Middle Aged. Neoplasm Staging. Platelet Count. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Autologous. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12827653.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CAO9126-25
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


22. Landfried K, Wolff D, Holler E: Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. Curr Opin Oncol; 2009 Jun;21 Suppl 1:S39-41
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A delay in acute GvHD after RIC may be explained by reduced conditioning-related inflammation and by altered allostimulatory capacities of recipient antigen-presenting cells (APC).
  • A higher frequency of chronic GvHD results from the almost exclusive use of peripheral blood stem cells, the absence of tolerance induction by current regimens for prophylactic immunosuppression and modified kinetics in the replacement of recipient APC.
  • Established acute and chronic GvHD requires standard treatment irrespective of the type of conditioning.
  • To improve long-term outcome in GvHD, pre-emptive strategies or more selective approaches aimed at immunomodulation rather than immunosuppression are needed.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Graft vs Host Disease / physiopathology. Stem Cell Transplantation / adverse effects. Transplantation Conditioning / methods
  • [MeSH-minor] Anti-Inflammatory Agents / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antigen-Presenting Cells / immunology. Antineoplastic Agents / therapeutic use. Etanercept. Humans. Immunoglobulin G / therapeutic use. Inflammation. Prednisolone / administration & dosage. Receptors, Tumor Necrosis Factor / therapeutic use

  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561413.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 3A189DH42V / alemtuzumab; 9PHQ9Y1OLM / Prednisolone; OP401G7OJC / Etanercept
  • [Number-of-references] 15
  •  go-up   go-down


23. Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T: Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol; 2003 Jun;169(6):2072-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two port site metastases (0.18% overall, 0.35% of histologically proved cases) occurred, including metastasis of small cell lung carcinoma after adrenalectomy and a residual mass following 2 cycles of chemotherapy after retroperitoneal lymph node dissection.
  • CONCLUSIONS: According to our experience the incidence of local recurrence and the risk of port site metastases is low and seems to be mainly related to the aggressiveness of the tumor and immunosuppression status of the patient, respectively rather than to technical aspects of the laparoscopic approach.
  • [MeSH-minor] Adrenalectomy. Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Seeding. Nephrectomy. Pelvis. Postoperative Complications. Prostatectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771722.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Zmonarski SC, Boratyńska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M: Kaposi's sarcoma in renal transplant recipients. Ann Transplant; 2005;10(2):59-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a spindle-shaped vascular cell tumor that occurs in the skin, lymphoid, respiratory and gastrointestinal tissues.
  • It may resemble aggressive malignant neoplasm in HIV-related or in post-transplant types but classic form may behave as benign, potentially controllable and reversible hyperplasia.
  • KS occurrence is associated with: type and dose of immunosuppression, chronic stimulation by foreign allograft antigens, viral infections (Herpes virus 8), anti rejection and induction therapy, etc.
  • There is no uniform schema of KS treatment in renal transplant recipients.
  • Immunosuppression must be reduced to the lowest levels which preserve allograft function.
  • After conversion to MMF regression of KS was observed, although low therapeutic MMF doses seem to be appropriate.
  • Sirolimus seems to inhibit the growth of established vascularized tumors and this effect is best realized with relatively low immunosuppressive doses of drug.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218035.001).
  • [ISSN] 1425-9524
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 25
  •  go-up   go-down


25. Cersosimo RJ: Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm; 2003 Aug 1;60(15):1531-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibodies in the treatment of cancer, Part 1.
  • Monoclonal antibodies used in the treatment of cancer are discussed.
  • Gemtuzumab ozogamicin is an active second-line therapy in older patients with acute myelogenous leukemia, but its role in combination regimens is unclear.
  • Alemtuzumab is a valuable option for salvage therapy of patients with chronic lymphocytic leukemia.
  • Ibritumomab tiuxetan delivers radioactive isotopes to tumor cells and is active against indolent lymphomas in patients who have relapsed after chemotherapy or rituximab therapy.
  • The most common adverse effects of monoclonal antibodies are myelosuppression, infusion-related reactions, and hypersensitivity reactions.
  • Alemtuzumab causes immunosuppression, increasing the risk of infection.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Neoplasms / therapy
  • [MeSH-minor] Aminoglycosides / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / therapeutic use. Clinical Trials as Topic. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / therapy. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12951753.001).
  • [ISSN] 1079-2082
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / gemtuzumab; 0 / ibritumomab tiuxetan; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 114
  •  go-up   go-down


26. Mischke A, Besier S, Walcher F, Waibel H, Brade V, Brandt C: [Spontaneous gas gangrene in a diabetic patient with Clostridium septicum]. Chirurg; 2005 Oct;76(10):983-6
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] "Spontaner" Gasbrand mit Kompartmentsyndrom bei einem diabetischen Patienten.
  • Atraumatic infections due to Clostridium septicum are known to be associated with immunosuppression or even malignancy.
  • In this case report, we present a patient with severe Clostridium septicum infection related to advanced colon cancer that had not previously been diagnosed.
  • Moreover, if patients with known colorectal or other malignancy develop septicaemia or spontaneous gas gangrene, clinicians should be aware of Clostridium septicum as one of the main causative agents, as early diagnosis and aggressive treatment are important to improve prognosis.
  • [MeSH-major] Adenocarcinoma / complications. Clostridium / isolation & purification. Colonic Neoplasms / complications. Diabetes Mellitus, Type 2 / complications. Gas Gangrene / etiology. Paraneoplastic Syndromes
  • [MeSH-minor] Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Clindamycin / administration & dosage. Clindamycin / therapeutic use. Colectomy. Colonoscopy. Debridement. Drug Therapy, Combination. Humans. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Penicillins / administration & dosage. Penicillins / therapeutic use. Radiography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Emerg Med. 2003 May;24(4):401-5 [12745042.001]
  • [Cites] Pol Merkur Lekarski. 2004 Oct;17(100):403-6 [15690715.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):353-6 [10705386.001]
  • [Cites] ANZ J Surg. 2001 Nov;71(11):647-9 [11736823.001]
  • [Cites] Rev Esp Enferm Dig. 2002 Jun;94(6):361-6 [12432593.001]
  • [Cites] Rev Infect Dis. 1990 Mar-Apr;12(2):286-96 [2330482.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):30-7 [2642585.001]
  • (PMID = 16021394.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Penicillins; 3U02EL437C / Clindamycin
  •  go-up   go-down


27. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, MacKinnon S: In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy; 2001;3(3):197-201
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients died from regimen-related complications.
  • Only two patients developed Grade II acute GvHD and only one had chronic GvHD.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Hematologic Neoplasms / therapy. Immunosuppression / methods. Stem Cell Transplantation / adverse effects. Stem Cell Transplantation / methods. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Drug Therapy, Combination. Female. Graft Survival / drug effects. Graft Survival / immunology. Humans. Immunosuppressive Agents / therapeutic use. Male. Melphalan / therapeutic use. Middle Aged. Recurrence. Survival Rate. Transplantation Chimera / immunology. Transplantation, Homologous / adverse effects. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171726.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


28. Kirman I, Asi Z, Carter J, Fowler R, Whelan RL: Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer. Surg Endosc; 2002 Apr;16(4):654-8
Hazardous Substances Data Bank. ALGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, surgery-related immunosuppression may diminish the effectiveness of pre-operative or early postoperative vaccines.
  • This problem may be overcome by limiting postoperative immunosuppression via the use of minimally invasive methods.
  • Alternatively, the impact of the vaccine may be improved by encapsulating the vaccine, plus adjuvant, which in theory, should extend exposure time.
  • [MeSH-major] Adenocarcinoma / therapy. Cancer Vaccines / therapeutic use. Colonic Neoplasms / therapy. Colorectal Neoplasms / pathology. Lipid A / analogs & derivatives. Lipid A / therapeutic use. Neoplasm Transplantation / methods
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Alginates / therapeutic use. Animals. Capsules / therapeutic use. Carbon Dioxide / therapeutic use. Drug Delivery Systems / methods. Female. Glucuronic Acid. Hexuronic Acids. Insufflation / methods. Laparotomy / methods. Mice. Mice, Inbred BALB C. Microspheres. Polysaccharides / therapeutic use. Postoperative Care / methods. Preoperative Care / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. ALGINIC ACID .
  • Hazardous Substances Data Bank. CALCIUM ALGINATE .
  • Hazardous Substances Data Bank. POTASSIUM ALGINATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1998 May;41(5):564-9 [9593237.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1162-9 [11984655.001]
  • [Cites] Surgery. 1982 Oct;92(4):786-92 [7123498.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):148-57 [10623705.001]
  • [Cites] Vaccine. 1996 Sep;14(13):1235-8 [8961511.001]
  • [Cites] J Infect Dis. 1995 May;171(5):1334-8 [7751713.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1671-6 [6704973.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3951-61 [4016762.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):345-50 [9950438.001]
  • [Cites] Hybridoma. 1999 Dec;18(6):543-6 [10626684.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):390-9 [8445413.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):589-94 [10673204.001]
  • [Cites] Aust N Z J Surg. 1988 Jan;58(1):43-6 [3046593.001]
  • [Cites] J Infect Dis. 1995 Sep;172(3):870-4 [7658086.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):771-6 [2412626.001]
  • [Cites] Anticancer Drugs. 1997 Mar;8(3):217-24 [9095325.001]
  • (PMID = 11972208.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Alginates; 0 / Cancer Vaccines; 0 / Capsules; 0 / Hexuronic Acids; 0 / Lipid A; 0 / Polysaccharides; 142M471B3J / Carbon Dioxide; 8A5D83Q4RW / Glucuronic Acid; 8C3Z4148WZ / alginic acid; MWC0ET1L2P / monophosphoryl lipid A
  •  go-up   go-down


29. Novitzky N, Rouskova A: Infectious complications following T-cell depleted hematopoietic stem-cell transplantation. Cytotherapy; 2001;3(3):165-73
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequent to the recovery of the blood parameters, the most prevalent infection was by herpes varicella/zoster in 20; another 17 developed herpes simplex.
  • Thirteen patients died of sepsis and in 10, it was related to GvHD or graft failure.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Immunosuppression / adverse effects. Infection / chemically induced. T-Lymphocytes / drug effects
  • [MeSH-minor] Adolescent. Adult. Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm. Bacterial Infections / chemically induced. Bacterial Infections / drug therapy. Bacterial Infections / immunology. Catheters, Indwelling / adverse effects. Child. Child, Preschool. Female. Hematopoiesis / drug effects. Hematopoiesis / immunology. Humans. Male. Middle Aged. Mycoses / chemically induced. Mycoses / drug therapy. Mycoses / immunology. Opportunistic Infections / chemically induced. Opportunistic Infections / drug therapy. Opportunistic Infections / immunology. Recovery of Function / drug effects. Recovery of Function / immunology. Recurrence. Retrospective Studies. Survival Rate. Treatment Failure. Virus Diseases / chemically induced. Virus Diseases / drug therapy. Virus Diseases / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171723.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


30. Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH: Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy; 2001;3(3):203-10
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been three transplant-related deaths secondary to viral pneumonitis or bacterial pneumonia.
  • Seven patients developed Grade I-II acute GvHD post-transplant.
  • Three patients had early progressive disease and six have relapsed from CR or progressed from PR (two of whom have achieved CR following DLI therapy).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Immunosuppression / methods. Lymphoproliferative Disorders / therapy. Melphalan / therapeutic use. Stem Cell Transplantation / methods. Transplantation Conditioning / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Humanized. Blood Donors. Disease Progression. Female. Graft Survival / drug effects. Graft Survival / immunology. Graft vs Host Disease / drug therapy. Graft vs Host Disease / immunology. Graft vs Host Disease / prevention & control. Humans. Lymphocyte Transfusion / methods. Lymphocyte Transfusion / trends. Male. Middle Aged. Monitoring, Physiologic. Secondary Prevention. Survival Rate. Transplantation Chimera / immunology. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171727.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 04079A1RDZ / Cytarabine; 3A189DH42V / alemtuzumab; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


31. Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG, Milligan D, MacKinnon S, Waldmann H, CAMPATH Users: CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy; 2001;3(3):145-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of CAMPATH-1G or CAMPATH-1H was associated with a low incidence of GvHD or rejection, though there were some differences that might be related to the longer half-life of the humanized antibody.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / adverse effects. Antibodies, Neoplasm / therapeutic use. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Immunosuppression / adverse effects. Immunosuppression / methods. Stem Cell Transplantation / adverse effects. T-Lymphocytes / drug effects
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Clinical Protocols. Clinical Trials as Topic. Humans. Multicenter Studies as Topic. Multivariate Analysis. Patient Selection. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171722.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Congresses; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


32. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol; 2010 Nov;46(3):308-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple drug resistance mechanisms in cancer.
  • Multiple drug resistance (multidrug resistance; MDR), a phenomenon whereby human tumours that acquire resistance to one type of therapy are found to be resistant to several other drugs that are often quite different in both structure and mode of action, has been recognised clinically for several decades.
  • An important advance in our understanding of MDR came with the identification of P-glycoprotein and other related transporters that were expressed in some cancer cells and could recognise and catalyse the efflux of diverse anticancer drugs from cells.
  • A second advance came from an understanding of the mechanism of programmed cell death or apoptosis, leading to MDR mediated by increased to resistance to anticancer drug-induced apoptosis.
  • A fourth advance was the delineation of features of the tumour microenvironment, including immunosuppression, which essentially provided tumour stem cells with an MDR phenotype.
  • Most published work on the overcoming of MDR has concentrated on inhibition of drug transporters but the complexity of mechanisms contributing demands a broad strategy for the development of methods to overcome MDR in a clinical setting.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis. Humans. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Med Chem. 2004 Apr;11(8):1031-9 [15083809.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):903-7 [18026089.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):567-8 [12571271.001]
  • [Cites] Nat Rev Drug Discov. 2006 Mar;5(3):219-34 [16518375.001]
  • [Cites] Nat Immunol. 2001 Apr;2(4):293-9 [11276199.001]
  • [Cites] Trends Mol Med. 2004 Mar;10(3):125-9 [15102355.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S3-8 [9272126.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7 [18040043.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2903-9 [16497299.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):924-32 [17285598.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):2956-9 [18838863.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3574-82 [19417029.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1775(2):237-62 [17572300.001]
  • [Cites] Int Rev Cytol. 2006;251:131-58 [16939779.001]
  • [Cites] FEMS Microbiol Rev. 1997 Aug;21(1):55-84 [9299702.001]
  • [Cites] Anticancer Drug Des. 1999 Jun;14(3):275-80 [10500502.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Jan;328(1):3-9 [18791064.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9903-7 [16777967.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):59-73 [18097448.001]
  • [Cites] Cell. 2010 May 14;141(4):583-94 [20478252.001]
  • [Cites] Leukemia. 2004 Jan;18(1):11-7 [14574329.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Sep;64(4):763-8 [19241078.001]
  • [Cites] Cancer Biol Ther. 2010 May 1;9(9):717-24 [20234184.001]
  • [Cites] Int J Cancer. 2003 Apr 20;104(4):504-11 [12584750.001]
  • [Cites] Methods Mol Biol. 2010;596:1-14 [19949917.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3551-7; discussion 3557 [18483233.001]
  • [Cites] Curr Pharm Des. 2004;10(16):1907-14 [15180527.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):225-33 [18176604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7753-8 [16682640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5431-6 [17374716.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):121-7 [18221031.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1390-3 [15483402.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(5):417-22 [10803926.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1603-8 [18347160.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6489-96 [14528273.001]
  • [Cites] Science. 2010 Jan 29;327(5965):542-5 [20110496.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2519-26 [18451212.001]
  • [Cites] Nat Cell Biol. 2010 May;12(5):468-76 [20418870.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1287-90 [16691209.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12128-33 [18713866.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7254-63 [18094405.001]
  • [Cites] Cancer Cell. 2006 Nov;10 (5):425-35 [17097564.001]
  • [Cites] J Surg Res. 2007 Sep;142(1):119-28 [17597158.001]
  • [Cites] Cell. 2008 Jun 13;133(6):1019-31 [18555778.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98 (2):380-7 [18219291.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):794-801 [15120035.001]
  • [Cites] Nat Rev Cancer. 2007 Jul;7(7):545-53 [17585334.001]
  • [Cites] Curr Oncol Rep. 2010 Mar;12(2):87-94 [20425592.001]
  • [Cites] Curr Protein Pept Sci. 2002 Oct;3(5):503-11 [12369998.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Jun;297(3):1088-98 [11356933.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):310-9 [2825971.001]
  • [Cites] Oncol Rep. 2008 Aug;20(2):265-70 [18636185.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8645-52 [14647458.001]
  • [Cites] Expert Opin Drug Discov. 2008 Feb;3(2):153-61 [23480219.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Dec;4(12):699-710 [18037874.001]
  • [Cites] Nat Rev Cancer. 2010 May;10(5):342-52 [20414202.001]
  • [Cites] Cancer Sci. 2010 Jan;101(1):16-21 [19860850.001]
  • [Cites] Mol Cell Biol. 2007 Jun;27(11):3920-35 [17403902.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):424-30 [9054956.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):507-18 [18538734.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):834-46 [17957189.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6713-21 [16166452.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] PLoS Biol. 2006 Mar;4(3):e51 [16464125.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8022-30 [18829560.001]
  • [Cites] Curr Drug Targets. 2003 Jan;4(1):31-43 [12528988.001]
  • [Cites] FEBS Lett. 2004 Jun 1;567(1):116-20 [15165903.001]
  • [Cites] Science. 1999 Dec 24;286(5449):2507-10 [10617466.001]
  • [Cites] Cell Death Differ. 2008 Sep;15(9):1499-509 [18464797.001]
  • [Cites] BioDrugs. 2002;16(2):97-103 [11985483.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Apr 18;368(4):930-6 [18279661.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):414-22 [15009724.001]
  • (PMID = 20717753.001).
  • [ISSN] 1559-0305
  • [Journal-full-title] Molecular biotechnology
  • [ISO-abbreviation] Mol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


33. Tzakis AG, Kato T, Nishida S, Levi DM, Tryphonopoulos P, Madariaga JR, De Faria W, Nery JR, Regev A, Vianna R, Miller J, Esquenazi V, Weppler D, Ruiz P: Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation; 2003 May 15;75(9):1512-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We combined alemtuzumab (Campath-1H, Berlex Laboratories, Montville, NJ) and tacrolimus (Tac) immunosuppression for intestinal and multivisceral transplantation.
  • Tac was substituted with sirolimus in case of Tac-related complications.
  • Four patients never developed acute rejection.
  • Infectious complications included a cytomegalovirus enteritis and four fungal infections (related to central venous access).
  • CONCLUSIONS: The combination of alemtuzumab and Tac therapy without steroid use seems to efficiently prevent acute rejection in a significant number of patients without causing frequent opportunistic infections.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Immunosuppressive Agents / administration & dosage. Intestines / transplantation. Tacrolimus / administration & dosage
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Drug Therapy, Combination. Graft Rejection / prevention & control. Humans. Liver Transplantation. Postoperative Complications. Prospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2005 Mar;11(3):361-3 [15719401.001]
  • (PMID = 12792506.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


34. Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA: Non-myeloablative transplantation. Hematology Am Soc Hematol Educ Program; 2002;:392-421
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The concept of utilizing enhanced immunosuppression rather than myeloablative cytotoxic conditioning has allowed the engraftment of allogeneic stem cells from related and unrelated donors with lower early transplant-related mortality (TRM) and morbidity.
  • This is not without risk, as the long-term effects of graft-versus-host disease (GVHD), it's treatment, or resulting complications and immunodeficiency may be life threatening.
  • However, this approach does allow the application of a potentially curative procedure to elderly or medically infirm patients who would not tolerate high-dose conditioning regimens.
  • Sandmaier, describes the current use of nonmyeloablative regimens and matched related or unrelated donors for the treatment of patients with CLL, CML, acute leukemia, MDS, lymphoma, and myeloma.
  • Maloney discusses the use of cytoreductive autologous followed by planned non-myeloablative allografts as treatment for patients with myeloma or NHL.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12446434.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA78902; United States / NHLBI NIH HHS / HL / HL36444
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Number-of-references] 149
  •  go-up   go-down


35. Voronov E, Reich E, Dotan S, Dransh P, Cohen I, Huszar M, Fogel M, Kleinman HK, White RM, Apte RN: Effects of IL-1 molecules on growth patterns of 3-MCA-induced cell lines: an interplay between immunogenicity and invasive potential. J Immunotoxicol; 2010 Mar;7(1):27-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, excessive inflammatory responses accompany tumorigenesis and tumor invasiveness, by the induction of immunosuppression.
  • We could not detect differences in cell surface markers related to immunogenicity, such as MHC Class I, co-stimulatory, or adhesion molecules between both types of cells.
  • However, more T-cells were observed at the inoculation site of tumor cells devoid of IL-1 and more pronounced parameters related to anti-tumor immunity were observed in the spleen (IL-12 and IFNgamma) of these mice, compared to mice bearing tumors derived from control mice, where host-derived IL-1 is present.
  • This suggests that manipulation of IL-1 could be useful in anti-tumor therapy, by reducing invasiveness and promoting immunity against the malignant cells.
  • [MeSH-major] Fibrosarcoma / immunology. Interleukin-1 / immunology. Neoplasm Invasiveness / immunology. Neoplasm Transplantation / immunology. Sarcoma, Experimental / immunology
  • [MeSH-minor] Animals. Aorta, Thoracic / drug effects. Cell Line, Tumor. Chick Embryo. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. Endothelial Cells / drug effects. Female. Methylcholanthrene / pharmacology. Mice. Mice, Inbred C57BL. Mice, Knockout. Neovascularization, Pathologic / immunology. Spleen / drug effects. Spleen / metabolism. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001788.001).
  • [ISSN] 1547-6901
  • [Journal-full-title] Journal of immunotoxicology
  • [ISO-abbreviation] J Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / Interleukin-1; 56-49-5 / Methylcholanthrene
  •  go-up   go-down


36. Tan J, Yang S, Cai J, Guo J, Huang L, Wu Z, Chen J, Liao L: Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Diabetes; 2008 Oct;57(10):2666-71
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.
  • OBJECTIVE: The aim of this study was to evaluate the efficiency and safety of simultaneous islet and kidney transplantation in patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.
  • RESEARCH DESIGN AND METHODS: Seven patients with type 1 diabetes and end-stage renal failure were transplanted with allogenic islets and kidneys procured from brain-dead donors.
  • To prevent organ rejection, patients received alemtuzumab for induction immunosuppression, followed by sirolimus and tacrolimus.
  • No glucocorticoids were given at any time.
  • No major procedure-related complications were observed.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Diabetes Mellitus, Type 1 / therapy. Islets of Langerhans Transplantation / methods. Kidney Failure, Chronic / therapy. Kidney Transplantation / methods
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Feasibility Studies. Female. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / therapeutic use. Kidney / drug effects. Kidney / metabolism. Kidney / physiology. Liver / drug effects. Liver / metabolism. Liver / physiology. Liver Function Tests. Male. Middle Aged. Pilot Projects. Sirolimus / administration & dosage. Sirolimus / therapeutic use. Tacrolimus / administration & dosage. Tacrolimus / therapeutic use


37. Jirasiritham S, Khunprakant R, Techawathanawanna N, Jirasiritham S, Mavichak V: Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report. Transplant Proc; 2010 Apr;42(3):987-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
  • This is a case report of a living related donor kidney transplantation using basiliximab induction and maintenance immunosuppression with cyclosporine, mycophenolate sodium, and steroid.
  • On the second posttransplant day, the patient developed acute antibody-mediated rejection, which was treated with plasmapheresis and intravenous immunoglobulin (IVIG).
  • Five days later, the graft had still not responded to the treatment.
  • The kidney graft responded well to the rescue treatment and the patient was discharged with a serum creatinine of 1.1 mg/mL and has been uneventfully followed in the outpatient clinic for 8 months.
  • The treatment of acute antibody-mediated rejection included plasmapheresis and IVIG.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Graft Rejection / drug therapy. Kidney Transplantation / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Creatinine / blood. Female. Glomerulonephritis / complications. Glomerulonephritis / surgery. Humans. Immunoglobulins, Intravenous / therapeutic use. Isoantibodies / immunology. Kidney Failure, Chronic / etiology. Kidney Failure, Chronic / surgery. Living Donors. Lymphocyte Count. Lymphocyte Depletion. Plasmapheresis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20430222.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunoglobulins, Intravenous; 0 / Isoantibodies; 3A189DH42V / alemtuzumab; AYI8EX34EU / Creatinine
  •  go-up   go-down


38. Wada H, Seki S, Takahashi T, Kawarabayashi N, Higuchi H, Habu Y, Sugahara S, Kazama T: Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology; 2007 Mar;106(3):499-506
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Many studies have shown that regional anesthesia improves postoperative outcome and particularly lessens infection by attenuating perioperative immunosuppression related to the stress response to surgery and general anesthesia.
  • [MeSH-major] Anesthetics, Combined / pharmacology. Cytokines / metabolism. Liver / pathology. Liver Neoplasms, Experimental / prevention & control. Lymphoma, T-Cell / drug therapy. Neoplasm Metastasis / prevention & control. T-Lymphocytes, Helper-Inducer / drug effects
  • [MeSH-minor] Analgesics, Opioid / pharmacology. Anesthesia, General / methods. Anesthesia, Spinal / methods. Anesthetics, Inhalation / pharmacology. Anesthetics, Local / pharmacology. Animals. Bupivacaine / pharmacology. Interferon-gamma / biosynthesis. Interferon-gamma / drug effects. Interleukin-4 / biosynthesis. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Male. Methyl Ethers / pharmacology. Mice. Mice, Inbred C57BL. Morphine / pharmacology. Neoplasm Transplantation. Nerve Block / methods. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. Sevoflurane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325508.001).
  • [ISSN] 0003-3022
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anesthetics, Combined; 0 / Anesthetics, Inhalation; 0 / Anesthetics, Local; 0 / Cytokines; 0 / Methyl Ethers; 207137-56-2 / Interleukin-4; 38LVP0K73A / sevoflurane; 76I7G6D29C / Morphine; 82115-62-6 / Interferon-gamma; Y8335394RO / Bupivacaine
  •  go-up   go-down


39. Khariwala SS, Kjaergaard J, Lorenz R, Van Lente F, Shu S, Strome M: Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope; 2006 May;116(5):814-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Everolimus (RAD) is an mTOR inhibitor closely related to rapamycin.
  • Within each group, animals were subdivided into four subgroups that received 1) 1 mg/kg everolimus twice a day, 2) 0.5 mg/kg everolimus twice a day, 3) 7.5 mg/kg cyclosporine per day, and 4) no treatment.
  • Intradermal tumors were measured three times per week.
  • Medication trough levels were measured in all treated animals.
  • Although most immunosuppressives are known to potentiate neoplastic disease, this study supports the use of everolimus immunosuppression in the face of prior malignancy.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Lung Neoplasms / secondary. Sirolimus / analogs & derivatives. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Administration Schedule. Everolimus. Female. Immunosuppressive Agents / pharmacology. Injections, Intravenous. Mice. Mice, Inbred C3H. Neoplasm Transplantation. Probability. Random Allocation. Reference Values. Sensitivity and Specificity. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Laryngoscope. 2006 Jul;116(7 Pt 1):1302
  • (PMID = 16652094.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down






Advertisement